US equities
|
MU
$895.48
▼-3.84%
TSLA
$352.77
▼-2.67%
NVDA
$215.97
▼-0.58%
AAPL
$344.34
▲+0.68%
SPCX
$145.71
▼-1.96%
META
$714.60
▼-3.00%
SNDK
$1,326.00
▼-4.93%
MSFT
$527.37
▼-2.24%
MU
$895.48
▼-3.84%
TSLA
$352.77
▼-2.67%
NVDA
$215.97
▼-0.58%
AAPL
$344.34
▲+0.68%
SPCX
$145.71
▼-1.96%
META
$714.60
▼-3.00%
SNDK
$1,326.00
▼-4.93%
MSFT
$527.37
▼-2.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Cosmos Health Inc. - Common Stock
(NQ:
COSM
)
0.3385
-0.0015 (-0.44%)
Delayed Quote
Updated: 1:01 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cosmos Health Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
October 14, 2026
● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform ● 60.5% of U.S. online checkout orders...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
October 13, 2026
Record day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date $902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-day...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
October 07, 2026
Record nine-month revenue of approximately $54.3 million - up 19%, or $8.7 million, from $45.6 million in the same period of 2025 Nine-month 2026 revenue nearly matches the whole of 2024 - when...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
October 01, 2026
More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded generics...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
September 29, 2026
Record Q2 2026 revenue of over $15 million , an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm Revenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
September 28, 2026
Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
September 15, 2026
7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today Secured orders for 1.04...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
September 14, 2026
Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock Positions Cosmos...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
September 11, 2026
500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presence...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
September 09, 2026
First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals , and...
From
Cosmos Health Inc.
Via
ACCESS Newswire
Cosmos Health: A Company Transformed — 2026 Year-to-Date
September 03, 2026
Record Revenue Across All Quarters Reported. Balance Sheet Deleveraged. Capital Structure Streamlined. Proprietary IP Filed in Four Global Markets. U.S. Market Entered. Global rollout of proprietary...
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions
August 28, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
August 24, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term
August 20, 2026
Innova is backed by leading investors and healthcare groups: Alkhabeer Capital, with more than $2.5 billion AUM; Tamer Group, a pharma manufacturing partner to Astellas and Daiichi Sankyo; and Cigalah...
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
August 19, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
July 27, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units
July 20, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases
July 17, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases
July 16, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases
July 15, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases
July 14, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases
July 13, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
July 13, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Launches Subscription Model
July 10, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases
July 09, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases
July 08, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases
July 07, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases
July 07, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
July 06, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases
July 02, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
